Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2026-03-12 Regulatory Filings
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of Regulatory Filings (RNS) as it is a specific corporate announcement required by financial regulators that does not fit into the other specialized categories like DIRS (insider trading) or SHA (share issuance).
2026-03-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. This type of filing is used to report significant changes in share ownership (often referred to as the 5% rule or major shareholding notification). It details the reporter's identity, the number of shares held, the purpose of holding (management influence), and specific details regarding collateral/pledge agreements. This aligns perfectly with the 'Major Shareholding Notification' category.
2026-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Syntekabio) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard mandatory disclosure filing in the Korean market (DART system) regarding financial performance updates. Since it provides specific financial highlights and reasons for the variance rather than being a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial results.
2026-02-12 Korean
전환가액의조정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing from a Korean company (Syntekabio) detailing the adjustment of the conversion price for its convertible bonds due to a decline in market price. This type of disclosure is a standard regulatory requirement for listed companies to inform shareholders of changes in capital structure and potential dilution. It fits the 'Regulatory Filings' category as it is a specific corporate announcement regarding financial instruments that does not fall into the other specialized categories like M&A, Dividends, or Share Repurchases.
2026-02-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details changes in share ownership by a major shareholder (Jung Jong-sun) of Syntekabio, including the number of shares held, the purpose of holding (management influence), and specific transaction details (market purchases). This falls under the category of 'Major Shareholding Notification' (MRQ), which covers filings related to significant changes in ownership levels.
2026-01-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (장내매수 - open market purchases) by a director (Jung Jong Sun) of Syntekabio. This is a standard regulatory filing for insider trading/director dealings in the Korean market.
2026-01-26 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.